iOnctura extends Series A to EUR20.1m
iOnctura SA, a clinical stage biopharmaceutical company, developing a pipeline of next generation molecules targeting cancer and fibrosis, has raised an additional EUR5.1 million bringing its total Series A financing to EUR20.1 million. New investor 3B Future Health Fund, previously known as Helsinn Investment Fund, SICAR joins the existing blue chip

